DiagnosTear Ltd. – CE Mark Approval

Tel Aviv (April 16, 2019) – BioLight is pleased to announce that today, its subsidiary DiagnosTear Ltd. ("**DiagnosTear**")[1], announced receipt of CE Mark approval for its product that is based on the TeaRx ™ technology, which is used to diagnose, personalize treatment and monitor Dry eye syndrome by examining the composition of the tear film (the "**Product**" and the "**Approval**").

As of receipt of the Approval, Diagnostear may market and sell the Product in all European countries that adopt the CE Mark regulatory standard. It should be noted that such marketing and sales require contacting local distributors, marketing activities and inclusion in indemnification codes as and if required in the various countries.

Diagnostear continues to focus on obtaining FDA approval and registration in the US and is aiming to launch the Product globally after receiving such approval

[1] Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).